Patients were randomly assigned to receive an extended-release aqueous-gel formulation of lanreotide ( Autogel -LSB- known in the United States as Depot -RSB- , Ipsen ) at a dose of @ mg ( @ patients ) or placebo ( @ patients ) once every @ days for @ weeks .